VHCP Management II’s Larimar Therapeutics LRMR Stock Holding History

VHCP Management II’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,790	Closed	-$468K	–	23
2016 Q3	$468K	Hold	11,790	–	–	0.24%	23
2016 Q2	$847K	Hold	11,790	–	–	0.51%	22
2016 Q1	$945K	Buy	+11,790	New	+$931K	0.62%	21

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VHCP Management II's LRMR Position: Q4 2016 in Review

VHCP Management II sold out of Larimar Therapeutics (LRMR) in Q4 2016, closing a stake of 11,790 shares — an estimated $468K sold.

VHCP Management II first reported a position in LRMR in Q1 2016 and held it in 3 quarters. The position peaked at $945K in Q1 2016. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

VHCP Management II reported no remaining Larimar Therapeutics position as of Q4 2016 after selling out during the quarter.
VHCP Management II sold 11,790 Larimar Therapeutics shares in Q4 2016, an estimated $468K.
VHCP Management II first reported a position in Larimar Therapeutics in Q1 2016 and held it in 3 quarters.
VHCP Management II's Larimar Therapeutics position peaked at $945K in Q1 2016.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on VHCP Management II's 13F filing for Q4 2016, filed 13 Feb 2017.